BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
7 Articles
7 Articles
Financial Post
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer Brain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient dataset First clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC […]
Oncology company BeOne Medicines announced results of clinical studies of drugs in research for liver and lung cancer, as well as advances in a trial for breast cancer, within the framework of the Congress of the European Society of Medical Oncology (ESMO 2026), held from 23 to 27 October in Madrid.The data reported on liver and lung correspond to phase 1 studies.Although the company highlighted the observed antitumor activity, the drugs continu…
GPC3 x 4-1BB, a potentially top-tier bispecific drug, achieves a 36% confirmed response rate at Phase 3 dose and a favorable safety profile in heavily pretreated liver cancer. Brain-penetrating PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared dataset of MTAP-deficient tumors. Initial clinical data of CEA-targeted ADC show encouraging and sustained response in high CEA […]
BeOne Medicines AG (ONC) Stock: 36% Liver Cancer Response Rate Fuels Breakthrough Potential
TLDR BeOne’s liver cancer drug posts a 36% response rate in a Phase 1 clinical study. BGB-B2033 shows a 74.1% six-month response durability rate at its target dose. BeOne’s lung cancer ADC delivers a 56% response rate in CEA-high tumor patients. PRMT5 inhibitor BGB-58067 records 30.8% intracranial responses in lung cancer. ONC shares slip 1.21% [...]
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
